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Abstract. Oseltamivir (Tamiﬂu®) is a prodrug of Ro 64-0802, a selective inhibitor of
inﬂuenza virus neuraminidase. There is a possible relationship between oseltamivir treatment
and neuropsychiatric adverse events; although this has not been established, close monitoring
is recommended on the prescription label. The objective of this study was to predict
interindividual variability of human exposure to oseltamivir and its active metabolite Ro 64-
0802. By leveraging mathematical models and computations, physiological parameters in
virtual subjects were generated with population means and coefﬁcient of variations collected
from the literature or produced experimentally. Postulated functional changes caused by
genetic mutations in four key molecules, carboxylesterase 1A1, P-glycoprotein, organic anion
transporter 3, and multidrug resistance-associated protein 4, were also taken into account.
One hundred thousand virtual subjects were generated per simulation, which was iterated 20
times with different random number generator seeds. Even in the most exaggerated case, the
systemic areas under the concentration–time curve (AUCs) of oseltamivir and Ro 64-0802
were increased by at most threefold compared with the population mean. By contrast, the
brain AUCs of oseltamivir and Ro 64-0802 were increased up to about sevenfold and 40-fold,
respectively, compared with the population means. This unexpectedly high exposure to
oseltamivir or Ro 64-0802, which occurs extremely rarely, might trigger adverse central
nervous system effects in the clinical setting.
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INTRODUCTION
Oseltamivir (Tamiﬂu®, Roche) is a prodrug of Ro 64-
0802, a selective inhibitor of inﬂuenza virus neuraminidase,
and is indicated for the treatment and prophylaxis of
inﬂuenza. After a few years on the market, neuropsychiatric
adverse events (NPAEs) such as abnormal behavior causing
self-injury, delirium, and convulsions, some of which had fatal
outcomes, were reported in a limited number of patients with
inﬂuenza who were receiving Tamiﬂu®. This occurred mainly
in pediatric/adolescent patients in Japan (1,2); in the crude
NPAE reporting rates (per 1,000,000 prescriptions) in chil-
dren (aged ≤16 years) and ks, respectively, were 99 and 28
events in Japan and 19 and 8 in the USA (2). Based on these
ﬁndings, a precaution was added to the drug label that
recommends close monitoring of patients immediately after
starting treatment with Tamiﬂu®.
The causality between Tamiﬂu® treatment and NPAEs
remains controversial. From the pharmacodynamic/
toxicodynamic perspective, several studies have reported central
nervous system (CNS) effects of oseltamivir and Ro 64-0802 in
experimental animals. Yoshino et al. reported increased dopa-
mine levels in the rat prefrontal cortex (3). Ono et al. reported
oseltamivir-induced hypothermia (4), and Suzuki and Masuda
demonstrated that coadministration of a dopamine receptor
agonist with oseltamivir increased the number of mice exhibiting
jump-down behavior (5). Usami et al. and Izumi et al. reported
that both oseltamivir andRo 64-0802 stimulate neural activities in
cultured rat hippocampus slices (6,7). However, from the
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pharmacokinetic perspective, 11C-labeled oseltamivir has limited
brain penetration in adult monkeys, who exhibited slightly lower
brain uptake clearance compared with infant and adolescent
monkeys (8). Seki et al. reported unchanged brain uptake of 11C-
labeled oseltamivir after poly I:C treatment, which simulates the
immune-activation condition, in juvenile monkeys (9).
As a principle of pharmacokinetics/pharmacodynamics
(toxicodynamics), the greater the drug exposure, the greater
the probability of undesirable drug effects/adverse events. In
addition, interindividual variability in drug exposure/responses
is caused by functional differences, either randomly or
nonrandomly, in drug-metabolizing enzymes, transporters,
and/or target molecules. From pharmacokinetic perspectives,
organ clearance is a hybrid parameter consisting of drug-related
parameters (unbound fraction and intrinsic clearance) and
physiological parameters (blood ﬂow and glomerular ﬁltration),
and is one of the major determinants of interindividual
variability of drug exposure. It is therefore important (1) to
identify key pharmacokinetic molecules that play important
roles in vivo, (2) to elucidate what nonrandom covariates would
affect the functions of these molecules, and (3) to take into
account variations in drug-related and physiological parameters.
At least four key components of intrinsic clearance have
been shown to play crucial roles in oseltamivir and Ro 64-
0802 pharmacokinetics in vitro and in animal studies: (1)
hepatic metabolism of oseltamivir by carboxylesterase (CES)-
1A1 to form Ro 64-0802, (2) probenecid-sensitive renal
tubular secretion of Ro 64-0802 by organic anion transporters
(OATs), (3) restriction of brain penetration of oseltamivir by
P-glycoprotein (P-gp), and (4) restriction of brain penetration
of Ro 64-0802 by OATs such as Oat3 and multidrug
resistance-associated protein 4 (Mrp4) in mice (10–12). For
each of these molecules, there are some genetic variants that
may exhibit gain of function or reduced function, but these
occur with limited frequency. Therefore, it is less likely that a
sort of Bworst-case^ scenario of the combination of signiﬁcant
genetic variants identiﬁed in multiple molecules are included,
identiﬁed, and analyzed in clinical trials.
The use of mathematical modeling and simulation may be
helpful in investigating these issues quantitatively because they
allow the incorporation of functional differences in intrinsic
clearance caused by genetic mutations as a ﬁxed effect, and
outliers can be generated virtually using a combination of
signiﬁcant genetic variants for multiple molecules.
Kinetic parameters can be affected by interindividual
variability, even within genotype groups. This means that
both the population means and variances (i.e., coefﬁcient of
variation, CV%) for each parameter should be taken into
account to predict interindividual variability in drug exposure.
This can also be incorporated into the modeling and
simulation.
In this study, we used a Monte Carlo simulation
approach to predict quantitatively the interindividual vari-
ability in oseltamivir and Ro 64-0802 exposure.
MATERIALS AND METHODS
Reagents
Oseltamivir phosphate and its active metabolite Ro 64-
0802 were synthesized as reported previously (13). [3H]p-
Aminohippurate (PAH) (4.1 Ci/mmol), [3H]estron-3-sulfate
(E-sul) (43.1 Ci/mmol), and [14C]tetraethylammonium (TEA)
(3.2 mCi/mmol) were purchased from PerkinElmer Life and
Analytical Sciences (Boston, MA). Unlabeled E-sul, PAH,
and probenecid were purchased from Sigma-Aldrich (St.
Louis, MO). Benzylpenicillin and cimetidine were purchased
from Wako Pure Chemicals (Osaka, Japan). Anti-human
OAT3 antibody was purchased from Trans Genic Inc.
(Kumamoto, Japan).
Animals
All experiments using animals in this study were carried
out according to the guidelines provided by the Institutional
Animal Care Committee (Graduate School of Pharmaceutical
Sciences, The University of Tokyo). Male FVB mice and
Mdr1a/1b(−/−) mice were obtained from Taconic Farms
(Germantown, NY) and maintained in Shimizu Laboratory
Supplies (Kyoto, Japan). The mice were maintained under
standard conditions with a reverse dark–light cycle. Food and
water were available ad libitum. All experiments using
animals in this study were carried out according to the
guidelines provided by the Institutional Animal Care Com-
mittee (Graduate School of Pharmaceutical Sciences, The
University of Tokyo, Tokyo, Japan).
Preparation of Human Kidney Slices and Uptake of Ro 64-
0802 by Human Kidney Slices
This study protocol was approved by the ethics review
boards of both the Graduate School of Pharmaceutical
Sciences, The University of Tokyo (Tokyo, Japan), and
Tokyo Women’s Medical University (Tokyo, Japan).
All participants provided their written informed consent.
Intact renal cortical tissues that had been obtained from ﬁve
surgically nephrectomized patients at Tokyo Women’s Med-
ical University from November 2007 to July 2008 were used.
Studies of the uptake by the human kidney slices were
performed as reported previously (14). Brieﬂy, after a 10-min
incubation at 37°C in the presence of the test compound, the
slices were quickly removed from the incubation buffer,
washed twice in ice-cold buffer, weighed, recovered in ice-
cold phosphate-buffered saline, and then homogenized using
a Polytron aggregate homogenizer (Kinematica, Lucerne,
Switzerland). The uptake activities of OAT1, OAT3, and
organic cation transporter 2 (OCT2) in the human kidney
slices were measured in every experiment using 0.1 μM tracer
or 1.0 mM excess PAH, E-sul, and TEA as reference
compounds for OAT1, OAT3, and OCT2, respectively.
Construction of OAT3 Variant cDNA
The full-length human OAT3 constructs used in this
study were subcloned into the pIRES2–EGFP vector as
reported previously (15). Each of the two nonsynonymous
OAT3 variants (I175V and A389V) identiﬁed in previous
reports (16) was then constructed by site-directed mutagen-
esis of the OAT3 reference-containing plasmid using the
QuickChange mutagenesis protocol (Stratagene, La Jolla,
CA). The sequence of each variant was conﬁrmed by
complete DNA sequencing to ensure that the appropriate
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nucleotide change had occurred and to conﬁrm that no other
alterations had been introduced. The primer sequences were
I175V: forward primer, 5′-CACCTTCCCCGTCTACATGG-
3′ , and reverse primer, 5′-CCATGTAGACGGGG
AAGGTG-3′, and A389V: forward primer, 5′-CAGG
CCGCTGTCCTGCTCCTG-3′, and reverse primer, 5′-
CAGGAGCAGGACGGCGGCCTG-3′.
Expression of OAT3 Variants in Mammalian Cells and
Transport Studies in OAT3-Transfected Human Embryonic
Kidney (HEK) 293 Cells
Each of the two nonsynonymous OAT3 variants (I175V
and A389V) was constructed by site-directed mutagenesis of
the wild-type OAT3 cDNA-containing plasmid using the
QuickChange mutagenesis protocol (Stratagene, La Jolla,
CA). DNA sequences of each variant were conﬁrmed using
an automated DNA sequencer (ABI PRISM 3100; Applied
Biosystems, Foster City, CA). Wild-type OAT3 and its
variant-overexpressing HEK293 cell lines were constructed
using Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s protocol, and stably transfected cells were
selected by G418 (0.8 mg/mL) (Invitrogen) in the culture
medium. HEK 293 cells transfected with empty vector (mock
cells) served as a negative control. The transport study was
performed as described previously (17). The uptake of each
ligand by OAT3-overexpressing transfectants was subtracted
from that of mock cells to obtain the OAT3-mediated uptake
clearance. The cell surface expression level of OAT3 was
quantiﬁed using a cell surface biotinylation method followed
by Western blot analysis, as described previously (18), and
was used for the calculation of the uptake properties of each
OAT3 variant.
Determination of Brain-to-Plasma Concentration Ratio of
Oseltamivir and Ro 64-0802 Following Subcutaneous Infu-
sion of Oseltamivir
Male FVB mice and Mdr1a/1b(−/−) mice (10–18 weeks
of age) weighing 25–30 g were used for these experiments.
An Alzet® osmotic pump (Cupertino, CA, 8 μL/h) was
implanted into mice under the skin on the back under
pentobarbital anesthesia (51.8 mg/kg). The mice received a
continuous subcutaneous infusion of oseltamivir at
400 nmol/h. Blood samples were collected from the
postcaval vein from mice under pentobarbital anesthesia
at 24 h after the dose, and the brain was excised
immediately. Plasma was obtained by centrifugation of
the blood samples (10,000g). The esterase inhibitor di-
chlorvos (200 μg/mL) was used to prevent ex vivo hydro-
lysis of oseltamivir to Ro 64-0802 in the blood and plasma
(19,20). The plasma and brain concentrations of Ro 64-
0802 were determined using liquid chromatography–mass
spectrometry analysis (10,11).
Parameter Estimation of the Clinical Pharmacokinetics of
Oseltamivir and Ro 64-0802
The plasma concentration–time proﬁles of oseltamivir
and Ro 64-0802 in humans after a single oral administration
of oseltamivir (150 mg qd) were obtained from a previous
report (21) using DataThief III software (available at http://
datathief.org/). Although the dose of 150 mg qd is not the
same as a clinical dose of 75 mg bid, obtaining key
pharmacokinetic parameters using this method is still
considered to be valid because of the dose-proportional
pharmacokinetics of each of oseltamivir and Ro 64-0802
(application form: http://www.info.pmda.go.jp/go/interview/
1/450045_6250021M1027_1_027_1F). The reported values
(application form) for unbound plasma protein binding
fraction and erythrocyte partitioning ratio of oseltamivir
and Ro 64-0802 were used. Assuming a hematocrit level of
0.45, Rb values were calculated as shown in Table I.
Considering the reported pharmacokinetic properties of
oseltamivir, we assumed that oseltamivir is readily absorbed
from the gastrointestinal tract (Fa · Fg = 1) and extensively
metabolized in the liver (the rest is eliminated by hepatic
metabolism and urinary excretion). We also assumed that
Ro 64-0802 is synthesized mainly in the liver and is excreted

































GFR 125 (mL/min)f 20.0j
CLr_plasma_oseltamivir 28.9 (L/h)
g –
CLr_blood_oseltamivir 379.5 (mL/min) 20.0
j
CLr_plasma_Ro 64-0802 20.0 (L/h)
g –
CLsec_blood_Ro 64-0802 330 (mL/min)
h –
CLint_renal_Ro 64-0802 305 (mL/min) 20.0
j




cObtained by in-house analysis (ﬁtted using Multi (Runge))




hCalculated assuming that Ro 64-0802 is not reabsorbed
i (24)
jAssumed
k Rb = (1 −Ht)/(erythrocyte partitioning ratio)











 Cblood; Ro 64‐0802
ð2Þ
dX liver; Ro 64‐0802
dt
¼ CLH;oseltamivir  Cblood;oseltamivir−k0eff
X liver; Ro 64‐0802 ð3Þ
Equations 1–3 represent the differential equations for
the blood concentrations of oseltamivir and Ro 64-0802, and
hepatic content of Ro 64-0802, respectively. C, ka, CLH, CLR,
Qh, k′eff, Vh, and Vd represent the drug concentration,
absorption rate constant, hepatic clearance, renal clearance,
hepatic blood ﬂow rate, elimination rate constant for the
hepatic sinusoidal efﬂux of Ro 64-0802, liver volume, and
distribution volume, respectively. Initial conditions are as
follows;
Eq: 1 : Cblood;oseltamivir ¼ 0
Eq: 2 : Cblood;Ro 64‐0802 ¼ 0
Eq: 3 : X liver;Ro 64‐0802 ¼ dose CLH;oseltamivirQH
Unknown parameters such as ka, k′eff, Vd, and CLH were
obtained using an iterative nonlinear least-square method
using the Multi (Runge) program (available at http://
www.pharm.kyoto-u.ac.jp/byoyaku/Kinetics/download.html).
CLH,oseltamivir/QH × dose was regarded as the initial
amount (X) of Ro 64-0802 in the liver.
Mathematical Models for Peripheral and Central Exposures
to Oseltamivir and Ro 64-0802
The areas under the blood concentration–time curve
(AUCblood) of oseltamivir and Ro 64-0802 after a single oral
administration of oseltamivir are represented as follows:


















where FH and CLtot represent hepatic availability and total
clearance, respectively. Assuming a well-stirred model, CLH,
oseltamivir and CLR, Ro 64-0802 were computed using randomly
generated simulated blood unbound fractions, blood ﬂow
rates, and intrinsic clearances. The functional changes in
CES1A1 caused by genetic variants were equal to the
changes in the hepatic intrinsic clearance of oseltamivir. In
addition, because the present study found that OAT3 but not
OAT1 plays crucial roles in the renal tubular secretion of Ro
64-0802, the functional changes in OAT3 caused by genetic
variants were equal to the changes in renal intrinsic clearance
of Ro 64-0802.
The areas under the brain concentration–time curve
(AUCbrain) of oseltamivir and Ro 64-0802 are represented as
follows (a schematic diagram is shown in Fig. 1):
Vbrain;oseltamivir  dCbrain;oseltamivirdt¼ fB;oseltamivir  Cblood;oseltamivir  PSinf;oseltamivir
− f brain;oseltamivir  Cbrain;oseltamivir  PSeff;oseltamivir þ CLmet;oseltamivir;brain
 
ð6Þ
Vbrain;Ro 64‐0802  dCbrain;Ro 64‐0802dt¼ fB;Ro 64‐0802  Cblood;Ro 64‐0802  PSinf;Ro 64‐0802
− f brain;Ro 64‐0802  Cbrain;Ro 64‐0802  PSeff;Ro 64‐0802
þ f brain;oseltamivir  Cbrain;oseltamivir  CLmet;oseltamivir;brain;
ð7Þ
where fB, fbrain, PSinf, PSeff, and CLmet represent the unbound
fraction in the blood, unbound fraction in the brain, brain
uptake clearance, brain efﬂux clearance, and brain metabolic
clearance, respectively. Initial conditions are as follows:
Eq: 6 : Cbrain;oseltamivir ¼ 0
Eq: 7 : Cbrain;Ro 64‐0802 ¼ 0
To determine the AUC, we integrated the time in the
above equations from 0 to inﬁnity as follows:








AUCblood;Ro 64‐0802  fB;Ro 64‐0802  PSinf;Ro 64‐0802 þAUCbrain;oseltamivir  f brain;oselatamivir  CLmet;oseltamivir;brain
f brain;Ro 64‐0802  PSeff;Ro 64‐0802
: (9)
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Monte Carlo Simulation
Monte Carlo simulation was conducted according to
the methods prescribed by Kato et al. (26). We ﬁrst
prepared several sets of 100,000 pseudorandom numbers
between 0 and 1, followed by the assignation of the
genotype of each transporter and metabolic enzyme based
on the allele frequencies of each genetic mutant. For
example, for a mutant whose allele frequency is 0.01, the
patient would be a carrier of this mutant if he/she received a
pseudorandom number from 0 to 0.01. By repeating this
procedure twice, we determine the diplotype of one gene in
each patient. As shown in Table I, using the mean and
CV% values (a log-normal distribution was assumed with
no covariance), we generated 100,000 virtual subjects with a
variety of blood ﬂow rates, protein binding ratios, glomer-
ular ﬁltration rates, and intrinsic clearances. The number of
virtual subjects per simulation was 100,000, and the
simulation was repeated 20 times to obtain summary
statistics. Simulations were computed using R (version
3.0.0).
Effects of Genetic Mutations on Protein Function
The effects of each genetic mutation on the transport and
metabolic activities of the molecules are summarized in
Table II. As for the brain exposure to oseltamivir and Ro
64-0802, some extreme cases were chosen to solve the
mathematical equations (Eqs. 8 and 9) more simply and
easily because inﬂux, metabolic, and efﬂux clearances could
not be determined quantitatively in humans. This was done
under the assumptions that (1) the efﬂux clearance of
oseltamivir is much higher than the metabolic clearance of
oseltamivir in the brain (efﬂux >> metabolism), (2) the efﬂux
clearance of oseltamivir is equal to the metabolic clearance of
oseltamivir in the brain (efﬂux =metabolism), (3) the efﬂux
clearance of oseltamivir is much lower than the metabolic
clearance of oseltamivir in the brain (efﬂux << metabolism),
and (4) the brain uptake of Ro 64-0802 is much larger than
the brain metabolism (synthesis << brain uptake, Ro 64-0802
only).
Based on the schematic diagram shown in Fig. 1, the
roles of transporters in the brain distribution of oseltamivir
and Ro 64-0802 were calculated. The Kp,brain of oseltamivir at
steady state was deﬁned as follows:
Kp; brain ¼ CbrainCplasma ð10Þ
f p  Cp  PSinf;oseltaivir;brain ¼ f brain  Cbrain
 PSeff;oseltaivir;brain; ð11Þ
where PSinf, PSeff, and fbrain represent the uptake, efﬂux, and
unbound fraction of oseltamivir in the brain, respectively. We
assumed that MDR1 plays a predominant role in oseltamivir
efﬂux and that no uptake transporter is involved in
oseltamivir inﬂux. Based on this assumption, Eq. 10 can be
represented as:
Kp; brain ¼ CbrainCplasma ¼
f p  PSinf;oseltamivir
f brain  PSeff;oseltamivir
¼ f p  PSdi f;oseltamivir
f brain  PSdif;oseltamivir þ PSMDR1;oseltamivir
  : ð12Þ
Because the present study showed that the Kp,brain was
19.9-fold higher in Mdr1a/1b(−/−) mice than in wild-type
mice, as per Eq. 12, P-gp-mediated efﬂux clearance
(PSMDR1,oseltamivir) was regarded as being 18.9-fold higher
than the clearance for passive diffusion (PSdif,oseltamivir). In
human brain capillary endothelial cells, CES1A1 expression
has been detected by immunohistochemical staining (35). The
effect of genetic mutation of CES1A1 on the metabolic
clearance of oseltamivir in the brain was assumed to be the
same as that in the liver (i.e., CES1A1 is considered to play
an exclusive role in brain metabolism of oseltamivir). Taking
these factors into consideration, the relative functional
changes in P-gp and CES1A1 attributed to genetic variants
compared with the wild-type were used to solve Eq. 8 to
obtain the fold-increase values for the brain AUC.
When investigating the brain distribution of Ro 64-0802,
we considered that OAT3 and MRP4 are responsible for the
efﬂux of Ro 64-0802 at the abluminal and luminal mem-
branes, respectively, in the blood–brain barrier (BBB). Inﬂux
and efﬂux clearance of Ro 64-0802 is represented as follows:
CLinf; Ro 64‐0802
¼ PSdif;Ro 64‐0802
  PSdif;Ro 64‐0802
2 PSdif;Ro 64‐0802 þ PSMRP4;Ro 64‐0802
ð13Þ
CLeff; Ro 64‐0802 ¼ PSdif;Ro 64‐0802 þ PSOAT3;Ro 64‐0802
 
 PSdif;Ro 64‐0802 þ PSMRP4;Ro 64‐0802
2 PSdif;R o64‐0802 þ PSMRP4;Ro 64‐0802 ; ð14Þ
where CLinf, CLeff, PSdif, PSOAT3, and PSMRP4 represent
intrinsic clearance, efﬂux clearance, clearance of passive
diffusion, and OAT3- and MRP4-mediated efﬂux clearance
of Ro 64-0802, respectively. Ose et al. (2008a) studied wild-
type, Oat3(−/−), and Mrp4(−/−) mice and reported that Oat3
and Mrp4 are important to the efﬂux of Ro 64-0802 across the
BBB. In Oat3(−/−) mice, which can be regarded as having
abolished Oat3 function, the elimination rate constant of Ro
64-0802 decreased from 0.0127 (/min) to 0.00317 (/min), and
we assumed the functional change in Oat3 caused by genetic
mutation directly affects the brain efﬂux clearance of Ro 64-
0802 (10). By contrast, PSdif,Ro 64-0802 and PSMRP4,Ro 64-0802
could not be obtained directly; PSdif,Ro 64-0802 was assumed to
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be negligibly small compared with PSMRP4,Ro 64-0802. The
relative functional changes in OAT3 and MRP4 caused by
genetic mutation were incorporated into the model, and Eqs. 13
and 14 were solved to obtain the brain AUC of Ro 64-0802.
Statistical Analyses
Student’s t test and one-way ANOVA followed by
Dunnett’s test were used to identify signiﬁcant differences
between groups when appropriate. Signiﬁcance was set at
p < 0.05.
RESULTS
Uptake of Ro 64-0802 by Human Kidney Slices and OAT1-
and OAT3-Overexpressing HEK293 Cells
Uptake of Ro 64-0802 (10 μM) by human kidney slices
was linear up to 10 min and was signiﬁcantly inhibited by
Fig. 1. Schematic diagrams of the model for the brain distribution of oseltamivir (a) and
Ro 64-0802 (b). The compartment model to describe the exchange of oseltamivir (a) and
Ro 64-0802 (b) between the blood and CNS side was shown across the BBB where active
transports mediated by P-gp and OAT3 and MRP4 at the BBB as well as passive diffusion
were taken into consideration for oseltamivir and Ro 64-0802, respectively. PSinf,Ro 64-0802
and PSeff,Ro 64-0802 that were used in Eqs. 13 and 14 were obtained assuming rapid
equilibrium in the BBB compartment
Table II. Summary of Genetic Mutations in OAT3, CES1A1, MRP4, and MDR1
Gene Amino acid change CDS position Genotype Allele/genotype/diplotype frequency Activity (%)







CES1A1 R182Hd G/A 0.024f 70.0d
(−816A)e A/C 0.286e 125e
C/C 0.105e 150e
MRP4g E757K 0.204 20.0

















l In-house data (supplemental Fig. 3A and B)
mActivity (%) of MDR1 haplotype for 3435C-2677A-1236T protein was assumed to be 100%
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1 mM PAH, benzylpenicillin, probenecid, or cimetidine
(63.5% ± 4.62%, 59.1%± 4.97%, 50.8%± 3.34%, and 67.1%
± 4.25% of control values, respectively, p < 0.05), but not by
1 mM TEA (108% ± 9%) (Supplemental Fig. 1A). A
signiﬁcant inhibitory effect of probenecid on the uptake was
observed at 10 μM and higher (Supplemental Fig. 1B),
whereas inhibition by cimetidine was observed only at
1 mM (Supplemental Fig. 1C).
The time-dependent uptake of Ro 64-0802 in OAT3-
overexpressing HEK293 cells was linear up to 10 min
(Supplemental Fig. 2B). The OAT3-mediated uptake clear-
ance of Ro 64-0802, deﬁned by subtracting from the uptake in
vector transfectants, was 1.29 μL/min/mg protein. OAT1-
speciﬁc uptake of Ro 64-0802 of OAT1 was rarely observed
(Supplemental Fig. 2A).
Characterization of the Nonsynonymous Mutants of OAT3
(I175V) and (A389V)
The uptake of [3H]E-sul (0.1 μM) andRo 64-0802 (5.0 μM)
by the empty vector, wild-type, and I175V and A389V OAT3-
overexpressing HEK293 cells was measured. The uptake of
[3H]E-sul and Ro 64-0802 was compared between the empty
vector-transfected cells and each type of OAT3-overexpressing
cell line (Supplemental Fig. 3A). The cell surface expression of
each OAT3 variant and wild-type OAT3 was quantiﬁed by
Western blot analysis followed by band density quantiﬁcation
(Supplemental Fig. 3B). Both I175V and A389V variants were
reduced function variants when the activity of the unit
transporter molecule was compared. The uptake values for E-
sul by cell surface I175V and A389V variants were 13.7%±
1.03% and 12.0%± 0.18%, respectively, compared with wild-
type OAT3. The respective uptake values for Ro 64-0802 were
13.6%± 1.27% and 9.5%± 0.09%.
Limited Penetration of Oseltamivir into the Brain Across the
BBB by P-gp
To characterize the P-gp-mediated efﬂux at the BBB,
oseltamivir was given by subcutaneous infusion for 24 h, and
the brain-to-plasma concentration (Kp,brain) of oseltamivir
was determined. The Kp,brain of oseltamivir was 19.9-fold
higher in Mdr1a/1b(−/−) mice than in wild-type mice (1.27 ±
0.263 vs 0.064 ± 0.008), whereas the Kp,brain of Ro 64-0802 did
not differ signiﬁcantly between Mdr1a/1b(−/−) mice and wild-
type mice (Supplemental Fig. 4).
A Model to Fit the Blood Concentration–Time Profile of
Oseltamivir and Ro 64-0802
A model of ﬁrst-order absorption with a one-
compartment disposition pharmacokinetic was built. The
pharmacokinetic parameters of oseltamivir and Ro 64-0802
were obtained based on data reported from phase 1 clinical
studies (21,36) and tested using a nonlinear least-square
method using the Multi (Runge) program. Simulated systemic
concentration–time curves for oseltamivir and Ro 64-0802
described the actual observed data well (Fig. 2). The obtained
extraction ratio in the liver (Eh) was 0.735, assuming an Fa ·
Fg of 1.
Prediction of Systemic Exposure to Oseltamivir and Ro 64-
0802
One hundred thousand virtual subjects were generated,
and the interindividual variabilities of systemic AUCs for
oseltamivir (Fig. 3) and Ro 64-0802 (Fig. 4) were computed
and analyzed using R. Those subjects carrying varying
genotypes for CES1A1 and OAT3, and their physiological
and pharmacokinetic parameters (e.g., blood ﬂow rates,
unbound fractions), were varied within the designated
population means (functional changes caused by single
nucleotide polymorphisms (SNPs) were also taken into
account as ﬁxed effects) and CV% under a log-normal
distribution (shown in Tables I and II). The median values
of population mean (%CV) out of 20 simulations for plasma
AUC of oseltamivir and Ro 64-0802 were 306 μg·h/L (25.3%)
and 6777 μg·h/L (15.5%), respectively, which were compara-
ble to the data reported previously (253 μg·h/L (24.5%) and
5436–6218 μg·h/L (12.2–23.8%)) (21). In our simulation, even
in the most exaggerated case, the systemic AUCs of
oseltamivir and Ro 64-0802 were increased by up to threefold
compared with the population means (Figs. 3 and 4; shown in
inset). The predicted population means and variabilities of
systemic AUCs for oseltamivir and Ro 64-0802 were similar
to those for the reported data (21,36).
Prediction of Brain Exposure to Oseltamivir and Ro 64-0802
Figure 1 shows schematic diagrams of the molecular
mechanisms responsible for the brain distribution of
oseltamivir (Fig. 1a) and Ro 64-0802 (Fig. 1b). The mathe-
matical models incorporated passive diffusion and
transporter-mediated membrane transport (MDR1 and
OAT3/MRP4 for brain efﬂux of oseltamivir and Ro 64-0802,
respectively). None of the permeability surface area products
(PS) and metabolic clearances in the human brain could be
obtained directly, and thus, some extreme cases were chosen
to solve the mathematical equations more simply and easily.
This was done by using (1) the relative fold changes in
subjects with genetic variants compared with wild type to
Fig. 2. Mathematical ﬁtting of blood concentration–time proﬁles of
oseltamivir and Ro 64-0802 after a single oral administration of
oseltamivir (150 mg). The blood concentration–time proﬁles of
oseltamivir (dotted line) and Ro 64-0802 (solid line) were ﬁtted using
the Multi (Runge) program. Open and closed squares represent the
observed blood concentrations of oseltamivir and Ro 64-0802,
respectively
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incorporate the inﬂuence of genetic mutations and (2) the
assumption that the brain pharmacokinetics of oseltamivir is
identical in mice and humans. The brain AUCs of oseltamivir
and Ro 64-0802 were increased by up to sevenfold (Fig. 5)
and 40-fold (Fig. 6), respectively, compared with the popula-
tion mean values, which contained a variety of combinations
of the variants.
Sensitivity Analysis
The inﬂuence of the functional changes in CES1, OAT3,
P-gp, and MRP4 caused by genetic variants in the systemic
and brain AUCs of oseltamivir and Ro 64-0802 was evaluated
by sensitivity analysis (Fig. 7). Variations from 10-fold
reductions up to 10-fold increases in each molecule were
assumed and compared with those of the wild type. The blood
AUC of oseltamivir was more sensitive to functional changes
in CES1A1, whereas the blood AUC of Ro 64-0802 was more
sensitive to functional changes in OAT3 and was hardly
affected by changes in CES1A1. The brain AUCs of
oseltamivir and Ro 64-0802 were dependent on the model
assumptions.
DISCUSSION
The clinical relevance of the abnormal behavior thought
to be caused by taking oseltamivir has not been clariﬁed. In
this study, we hypothesized that the combination of the
genetic mutations associated with signiﬁcant functional
changes would alter the pharmacokinetics of oseltamivir
and/or Ro 64-0802, which might produce the unexpected
incidents with rare frequency. Using a Monte Carlo approach,
we virtually predicted and depicted the distribution of
systemic and brain exposures (AUCs) for oseltamivir and
Ro 64-0802 by taking into account the interindividual
variability of each pharmacokinetic parameter such as blood
ﬂow rate, unbound protein binding fraction, and the effects of
genetic mutations on intrinsic clearance.
We conducted some in vitro and in vivo experiments to
obtain an insight into the pharmacokinetics of oseltamivir and
Ro 64-0802. First, the mechanism responsible for the renal
tubular secretion of Ro 64-0802, the major elimination
pathway from the systemic circulation, was characterized
in vitro. We have previously demonstrated that the uptake in
human kidney slices correlates linearly with the renal
clearance of the corresponding compounds (37). The results
of the uptake study with human kidney slices suggested that
OATs, but not organic cation transporters, are responsible for
renal uptake of Ro 64-0802. Hill et al. reported the
involvement of OAT1 by demonstrating signiﬁcant uptake
of Ro 64-0802 in OAT1-overexpressing cell lines (36).
However, in the present study, OAT1 hardly recognized Ro
64-0802 as a substrate, but OAT3 did. Hill et al. denied the
possibility of OAT3 involvement, as shown by the ﬁnding of
no signiﬁcant clinical drug–drug interaction with cimetidine,
an OAT3 substrate. However, at the concentration relevant to
the maximum unbound plasma concentration of cimetidine at
a dose of 400 mg (5.2 μM) (38), the inhibitory effect of
cimetidine (1–100 μM) on Ro 64-0802 uptake by human
kidney slices was not observed. This indicates that the
absence of a clinical drug interaction with cimetidine on the
renal uptake of Ro 64-0802 may not exclude the contribution
of OAT3. In addition, we found that two nonsynonymous
variants of OAT3 (I175V and A389V) are variants with
signiﬁcantly reduced function in vitro.
Second, the Kp,brain of oseltamivir in Mdr1a/1b(−/−) mice
was determined after a longer duration than in the previous
report (120 min) (11). The Kp,brain of oseltamivir was about
threefold higher at 24 h than at 2 h. All of the information
was included in the subsequent model analysis.
Using 100,000 virtual subjects with a series of pharma-
cokinetic parameters, we computed the individual blood and
brain AUCs of oseltamivir and Ro 64-0802. Because of the
nature of our interest in the maximum fold increase in AUC
in the most extreme case within the virtual population, the
values were susceptible to random seeding. We therefore
repeated the simulations 20 times and took the median values
to bolster the prediction probability. The maximum brain
AUCs of oseltamivir and Ro 64-0802 were about sevenfold
and 40-fold higher, respectively, compared with the popula-
tion mean, which included a variety of combinations of the
variants. The EC50 of oseltamivir and Ro 64-0802 against the
abnormal population synchronized burst in cultured rat
hippocampus slices were 10.2 and 0.7 μM, respectively (7),
Fig. 3. Distribution of predicted plasma AUC for oseltamivir in
100,000 virtual subjects after a single oral administration of
oseltamivir (150 mg). The histogram shows representative results of
one of 20 simulations. The inset figure represents a box plot of the
90th, 99th, 99.9th, 99.99th, and 100th percentiles of fold increases
relative to the population mean and summarized from 20 simulations
Fig. 4. Distribution of predicted plasma AUC of Ro 64-0802 in
100,000 virtual subjects after single oral administration of oseltamivir
(150 mg). The histogram shows a representative ﬁgure of one of 20
simulations. The inset figure represents a box plot of the 90th, 99th,
99.9th, 99.99th, and 100th percentiles of fold increases relative to the
population mean and summarized from 20 simulations
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which are greater than their concentrations in the cerebro-
spinal ﬂuid (CSF) (7.7 and 67.8 nM, for oseltamivir and Ro
64-0802, respectively (39)) after a single oral administration
of oseltamivir (150 mg) in humans. The clinical dose of
oseltamivir is 75 mg twice daily for adults and even less for
children. However, assuming the most extreme cases, the CSF
concentration of Ro 64-0802 could exceed the EC50 and may
trigger NPAEs of oseltamivir.
The effects of functional changes in CES1A1, OAT3,
MRP4, and MDR1 on the blood and brain AUCs of
oseltamivir and Ro 64-0802 were calculated further by
sensitivity analysis. As expected, sensitivity analysis revealed
that the brain AUC of oseltamivir is highly sensitive to the
CES1A1 function in all scenarios (Fig. 7c–e) and to MDR1 in
some cases when the brain efﬂux of oseltamivir could not be
ignored. In particular, because the functional changes in
Fig. 5. Summary of the brain AUC of oseltamivir after a single oral administration of oseltamivir (150 mg). The ﬁgures
represent box plots of the 90th, 99th, 99.9th, 99.99th, and 100th percentiles of fold increases relative to the population mean
and summarized from 20 simulations under the assumptions that the efﬂux clearance of oseltamivir is much higher than the
metabolic clearance of oseltamivir in the brain (left), equal to the metabolic clearance of oseltamivir in the brain (middle),
and much less than the metabolic clearance of oseltamivir in the brain (right)
Fig. 6. Summary of the brain AUC for Ro 64-0802 after a single oral administration of oseltamivir
(150 mg). The ﬁgures represent box plots of the 90th, 99th, 99.9th, 99.99th, and 100th percentiles of
fold increases relative to the population mean and summarized from 20 simulations under the
assumptions that the efﬂux clearance of oseltamivir is much higher than the metabolic clearance of
oseltamivir in the brain (top left), the efﬂux clearance of oseltamivir is equal to the metabolic
clearance of oseltamivir in the brain (top right), the efﬂux clearance of oseltamivir is much lower
than the metabolic clearance of oseltamivir in the brain (bottom left), and the brain uptake of Ro
64-0802 is much larger than the brain metabolism (bottom right)
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CES1A1 contribute both systemically and centrally, the brain
AUCs of oseltamivir are synergistically affected by CES1A1
function. By contrast, the AUC of Ro 64-0802 in the brain
was affected predominantly by OAT3 in all scenarios (Fig. 7f–
i) and by MRP4 when the brain uptake of Ro 64-0802 is
greater than the rate of Ro 64-0802 synthesis in the brain
(Fig. 7i). When the brain uptake of Ro 64-0802 is negligible
compared with the rate of Ro 64-0802 synthesis in the brain,
the AUC of Ro 64-0802 in the brain will be signiﬁcantly
affected by CES1A1 (Fig. 7h) and MDR1 (Fig. 7f), depending
on the predominance of each metabolite there and efﬂux
clearance of oseltamivir from the brain. Furthermore, we note
that, even for the brain AUC for Ro 64-0802, reduced but not
increased CES1A1 function caused an increase in the brain
AUC for Ro 64-0802. This was seen in a scenario where brain
metabolism of oseltamivir cannot be ruled out, which can be
accounted for by synergistically increased brain AUCs for
oseltamivir.
Sensitivity analysis showed clearly the importance of
CES1A1 in AUCbrain of oseltamivir (Fig. 7c–e) and AUCbrain
of Ro 64-0802 in a certain scenario (Fig. 7h). These data
suggest that the hydrolysis activity of oseltamivir in the
human brain should be examined. The lack of key informa-
tion can be a critical constraint when performing this type of
simulation. However, the use of a mathematical model
allowed us to conduct uncertainty/sensitivity analysis to
identify the effects of uncertainties, some of which are
unknowns. This is one of the key aspects of the model-
based approach.
Tarkiainen et al. investigated the effects of the CES1A1
SNP Gly143Glu (rs121912777), which reduced the catalytic
efﬁciency by more than 80% (Vmax/Km) of CES1A1 for p-
nitrophenyl acetate in vitro (40). In healthy Caucasian Finnish
volunteers, the AUCinf values in one homozygous carrier
were ∼290% and ∼360% larger for oseltamivir and 20% and
27% smaller for Ro 64-0802 than the mean values in
heterozygous carriers and noncarriers, respectively (41). Our
predictions are in agreement with these ﬁndings. According
to our simulation, the oseltamivir level in the brain will be
markedly higher in a homozygous carrier than in a noncarrier.
We note the following limitations in the present study.
First, we applied the mouse BBB characteristics to predict
Fig. 7. Sensitivity analysis of the functional changes in each molecule. Each column represents the
predictions when the functions of OAT3, MRP4, MDR1, and CES1A1 are (from left to right) intact (100%),
decreased to 10% and 33%, and increased to 300% and 1000% compared with the wild type. The vertical
axis represents the relative AUC ratio for each prediction normalized by the AUC obtained under the
condition of intact function for all molecules (100%). The ﬁgures resrepresent blood AUC of a oseltamivir,
b Ro 64-0802 and brain AUCs in the extreme cases of c efﬂux >> metabolism, d efﬂux =metabolism, e
efﬂux << metabolism for oseltamivir, f efﬂux >> metabolism, g efﬂux =metabolism, h efﬂux << metabolism
for oseltamivir in the brain under the condition of synthesis >> uptake for Ro 64-0802 in the brain, and i
synthesis << brain uptake for Ro 64-0802 in the brain
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human brain exposure under normal conditions. We also
assumed that MRP4-mediated brain efﬂux of Ro 64-0802 is
greater than the passive clearance. Therefore, the impact of
functional changes in MRP4 directly inﬂuenced the brain
inﬂux clearance of Ro 64-0802, but not the efﬂux clearance
because of uptake at the abluminal membrane being a rate-
determining process in the overall efﬂux across the BBB
under such condition. This assumption might also exaggerate
the impact of functional changes in MRP4 on brain AUC of
Ro 64-0802, as seen in Fig. 7i. Second, the effects of genetic
mutations on the function of MDR1 are particularly contro-
versial. Third, the CES1A1-mediated hydrolysis of
oseltamivir has not been elucidated, but was assumed to be
much higher than that of nonenzymatic hydrolysis in the
human brain. Finally, although age and body weight have
been shown to be signiﬁcant covariates for total clearance of
Ro 64-0802 (application form), because of a lack of more
detailed information, pharmacokinetic parameters used in
this study were obtained based on data from adults. One must
be prudent when interpreting the simulation outcomes
because of the uncertainties within these assumptions. On
the other hand, when performing this sort of model-based risk
assessment, some assumptions are necessary because not all
of the information is available. We believe it is more effective
to build mathematical models and run simulations under
several assumptions with uncertainties and to identify the key
components and molecules that play pivotal roles. This
practice improves the efﬁciency and effectiveness of drug
research and development (and even applications in
postmarketing surveillance) because it always provides quan-
titative answers to fundamental questions and insights into
the worst-case scenario based on current knowledge and
helps to prioritize the uncertainties and assumptions that
should be solved.
Concerning the effects of genetic mutation on MDR1, a
positron emission tomography study using 11C-verapamil
found no signiﬁcant differences between three haplotypes of
the MDR1 gene: SNPs C1236T, G2677T, and C3435T (42).
However, substrate speciﬁcity might exist. In support of this
hypothesis, Kimchi-Sarfaty et al. reported that the afﬁnities of
MDR1 against cyclosporine A, verapamil, and rapamycin
differed between some variants despite the lack of differences
in amino acid sequences (43).
Finally, although the clinical relevance of these ﬁndings
needs further investigation and should be interpreted care-
fully, the risk assessment approach using Monte Carlo
simulation and including interindividual variability may be
useful in understanding unexpected drug exposure that could
cause rare, but unacceptable, future events. More impor-
tantly, the model-based approach offers an iterative Blearn
and conﬁrm^ cycle including insightful information such as
what is known and unknown, the magnitude of uncertainty,
and whether and how to proceed to the next step.
CONCLUSION
The Monte Carlo simulation analyses showed the
systemic AUC of oseltamivir and Ro 64-0802 were increased
by at most threefold, whereas the brain AUCs were increased
up to about sevenfold (oseltamivir) and 40-fold (Ro 64-0802),
compared with the population means. The risk assessment
approach by using Monte Carlo simulation taking inter-
individual variability (caused by inherent genetic mutations
as well as random variability) into consideration is useful to
better understand the unexpected drug exposure which could
cause unacceptable events that might happen with rare
frequency.
AUC, area under the curve; BBB, blood–brain barrier;
CES, carboxylesterase; CNS, central nervous system; CSF,
cerebrospinal ﬂuid; CV, coefﬁcient of variations; Eh, extrac-
tion in the liver; EC50, half maximal effective concentration;
E-sul, estron-3-sulfate; Fa, fraction of absorbed; Fg, availabil-
ity in the intestine; HEK, human embryonic kidney; MDR,
multidrug resistance; MRP, multidrug resistance-associated
protein; NPAEs, neuropsychiatric adverse events; OAT,
organic anion transporter; OCT; organic cation transporter;
PAH, p-aminohippurate; P-gp, P-glycoprotein; PS, permeabil-
ity surface area product; TEA, tetraethylammonium
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